Initial Testosterone Therapy for First-Time Users
For a first-time testosterone user with confirmed hypogonadism, start with either transdermal testosterone gel (preferred for initiation) or intramuscular testosterone enanthate/cypionate, aiming to achieve mid-normal testosterone levels (450-600 ng/dL). 1, 2, 3
Formulation Selection
Transdermal Gel (Preferred Initial Option)
- Transdermal testosterone should be preferred for initiation of therapy because it provides more stable serum levels and allows easier dose titration 1, 4
- Typical starting dose: 50-100 mg daily applied to shoulders, upper arms, or abdomen
- Assess testosterone levels after 1 week of treatment, anytime during the day
- Adjust dose to achieve mid-normal range (450-600 ng/dL)
- Critical safety warning: Patients must cover application sites with clothing and wash skin with soap and water before skin-to-skin contact to prevent testosterone transfer to women or children 5
Intramuscular Injection (Cost-Effective Alternative)
- Consider intramuscular formulations when cost is a significant factor, as they are considerably less expensive with similar clinical effectiveness 6
- Testosterone enanthate or cypionate: typical starting dose 75-100 mg weekly or 150-200 mg every 2 weeks
- Measure testosterone levels midway between injections at 3-6 months
- Target range: 350-700 ng/dL (if >700 ng/dL or <350 ng/dL, adjust dose or frequency) 1, 2
Important nuance on injection frequency: While every-two-week dosing is traditional, weekly injections often provide more stable symptom control and reduce peak-trough fluctuations that can cause mood swings, acne, or late-cycle fatigue 7. For patients experiencing symptom cycling on bi-weekly dosing, consider weekly or even more frequent lower-dose injections rather than increasing total dose.
Monitoring Protocol
Initial 3-6 Month Visit (Critical)
- Evaluate symptom response (sexual function, energy, mood)
- Check testosterone level: 3-6 months after initiation 1, 2
- Check hematocrit: baseline and at 3-6 months (stop if >54%) 1, 2
- PSA and digital rectal exam: For men ≥40 years with baseline PSA >0.6 ng/mL, check at 3-6 months 1
Annual Monitoring
- Testosterone level
- Hematocrit (stop therapy if >54%; evaluate for hypoxia/sleep apnea before restarting at reduced dose) 1, 2
- PSA and digital rectal exam (per age-appropriate screening guidelines)
- Symptom assessment
Red Flags Requiring Urological Consultation
- PSA increase >1.4 ng/mL within any 12-month period 1, 2
- PSA velocity >0.4 ng/mL/year (after 6 months of therapy) 1
- Confirmed PSA >4.0 ng/mL 5
- Prostatic abnormality on digital rectal exam 1, 2
- AUA/IPSS symptom score >19 1
Absolute Contraindications
- Untreated prostate cancer 4
- Untreated breast cancer 4
- Severe heart failure 4
- Hematocrit >50% (relative contraindication; requires evaluation before initiating) 1
Critical Pitfalls to Avoid
Do not start therapy without confirmed diagnosis: Requires two separate morning testosterone measurements showing low levels (<300-350 ng/dL) plus compatible symptoms 2, 8, 9
Do not measure testosterone at random times: Always use morning fasting samples for diagnosis 4
Do not automatically default to every-two-week injectable dosing: This creates unnecessary peak-trough variation in many patients 7
Do not continue therapy without symptom improvement: Reevaluate at 12 months and discontinue if no improvement in target symptoms 6
Do not ignore formulation-specific monitoring:
Treatment Goals
- Target testosterone levels: Mid-normal range (450-600 ng/dL) 2, 3
- Primary outcome: Improvement in sexual function (strongest evidence) 5, 4, 8
- Secondary outcomes: Body composition, bone density (moderate evidence); energy/mood (weak/inconsistent evidence) 8, 10
The goal is physiologic replacement with stable symptoms and interpretable laboratory results, not maximizing testosterone levels 7, 3.